{"id":4550,"date":"2026-10-13T16:14:10","date_gmt":"2026-10-13T16:14:10","guid":{"rendered":"https:\/\/nhdbio.com\/?page_id=4550"},"modified":"2026-10-13T16:14:10","modified_gmt":"2026-10-13T16:14:10","slug":"%e8%82%bd-d-l-%e6%9e%84%e5%9e%8b%e6%b5%8b%e8%af%95","status":"publish","type":"page","link":"https:\/\/nhdbio.com\/cn\/analytical-methods\/peptide-d-l-configuration-testing\/","title":{"rendered":"\u5206\u5b50\u91cf\u5bf9\u4e0a\u4e86\uff0c\u4e3a\u4ec0\u4e48\u8fd8\u4e0d\u80fd\u786e\u8ba4\u80bd\u7684D\/L\u6784\u578b\uff1f"},"content":{"rendered":"
\n

D \u548c L \u6307\u6c28\u57fa\u9178\u7684\u7a7a\u95f4\u6392\u5217\u3002\u5b83\u4eec\u53ef\u80fd\u5177\u6709\u76f8\u540c\u7684\u8d28\u91cf\uff0c\u56e0\u6b64\u68c0\u67e5\u5206\u5b50\u91cf\u548c\u68c0\u67e5\u624b\u6027\u662f\u4e24\u4e2a\u4e0d\u540c\u7684\u95ee\u9898\u3002<\/p>\n

\"Comic
Editorial illustration; not an experimental photograph.<\/figcaption><\/figure>\n

D and L, like a pair of left and right hands that cannot be superimposed<\/h3>\n

Many amino acids are chiral: the composition is the same, but the spatial arrangement has mirror-image forms. Glycine is a common exception because it has no corresponding chiral center. D\/L naming also cannot simply be equated with writing the entire peptide backwards.<\/p>\n

Replacing the D\/L configuration at just one position of a peptide and changing the entire peptide into its complete mirror form are also not exactly the same situation analytically.<\/p>\n

Why doesn't a mass match answer all the questions?<\/h3>\n

Changing only the D\/L configuration of a certain amino acid can leave the composition and theoretical mass unchanged. Therefore, a matching intact molecular mass cannot by itself prove that the configuration at the required position is correct.<\/p>\n

Whether ordinary non-chiral separation can distinguish them depends on the specific molecule and method. Fully mirror-image materials and diastereomeric materials formed by changing some positions should also be discussed separately; one cannot say that all chromatography or all mass spectrometry can always distinguish them or can never distinguish them.<\/p>\n

How can additional evidence be sought?<\/h3>\n

Clearly raise the configuration question with the testing party, then discuss suitable methods and reference standards. This may involve chiral chromatography, chiral amino acid analysis after appropriate treatment, or other methods validated for the specific material.<\/p>\n

Some studies use specific tandem mass spectrometry conditions to distinguish diastereomeric peptides containing D-amino acids. This shows that a specific method can provide information, not that routine LC-MS mass results have already completed all chiral confirmation.<\/p>\n

The treatment process itself must also be included in the check<\/h3>\n

If the method requires hydrolysis or other treatment, it is also necessary to assess whether the treatment introduces configurational changes. The final method must be able to answer the question about the original material, not merely measure some property of the treated product.<\/p>\n

When ordering, write the D positions, terminal modifications, and full sequence clearly. Labeling only "D peptide" can easily omit which positions need to be D and whether reverse order is also required.<\/p>\n

How should an accurate testing request be written?<\/h3>\n

You can write: We wish to confirm the D\/L configuration at specific positions in the given sequence; please state the analytical evidence that can be provided, the methods used, reference standards, and method limitations. This is closer to the identity that actually needs to be confirmed than "a correct molecular weight is enough."<\/p>\n

Three questions, three types of evidence needs<\/figcaption>
\n
Whether the mass matches the expected composition<\/b>Is intact mass alone enough: Intact mass can provide information, but it needs to be combined with other identity records<\/span><\/div>\n
Whether the amino acid sequence is correct<\/b>Is intact mass alone enough: Further sequence evidence is usually needed<\/span><\/div>\n
Whether the specified position is D<\/b>Is intact mass alone enough: Applicable evidence addressing the configuration question is needed<\/span><\/div>\n<\/div>
Teaching summary. Check the explanation and original sources; this is not a to-scale molecular model or a product test result.<\/figcaption><\/figure>\n
\n\n\n\n\n\n\n\n
Three questions, three types of evidence needs<\/caption>\n
\u95ee\u9898<\/th>\nIs intact mass alone enough<\/th>\n<\/tr>\n<\/thead>\n
Whether the mass matches the expected composition<\/td>\nIntact mass can provide information, but it needs to be combined with other identity records<\/td>\n<\/tr>\n
Whether the amino acid sequence is correct<\/td>\nFurther sequence evidence is usually needed<\/td>\n<\/tr>\n
Whether the specified position is D<\/td>\nApplicable evidence addressing the configuration question is needed<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\n

What did the original method study do?<\/h3>\n

Adams and Zubarev compared ECD and CAD fragmentation in 2005 using models including tryptophan cage, a lactoferrin peptide and dermorphin. Their abstract reports calibration accuracy of 1% for ECD and 3\u20135% for CAD for relative D-residue abundance in the studied diastereomer mixtures. These are study-specific calibration results, not routine LC-MS detection limits or guaranteed errors.<\/p>\n

Request mass and stereochemical confirmation separately<\/h3>\n

A mass match means the measured intact mass is compatible with the target record. Confirming configuration needs a method and controls that distinguish the relevant stereoisomers. If the report shows only an intact-mass peak, mark configuration as \u201cnot established by this report\u201d rather than assuming it passed.<\/p>\n<\/section>\n

Original sources and further reading<\/h3>\n